Global Intravenous Immunoglobulin (IVIg) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Intravenous Immunoglobulin (IVIg) Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Intravenous Immunoglobulin (IVIG) is a solution of highly purified Immunoglobulin G, derived from large pools of human plasma that contain antibodies against a broad spectrum of bacterial and viral agents.

Market Overview:

The latest research study on the global Intravenous Immunoglobulin (IVIg) market finds that the global Intravenous Immunoglobulin (IVIg) market reached a value of USD 13315.76 million in 2022. It’s expected that the market will achieve USD 24771.66 million by 2028, exhibiting a CAGR of 10.9% during the forecast period.

Influence of COVID-19 Outbreak on Intravenous Immunoglobulin (IVIg) Industry Development

After the epidemic is over, the people will have higher demand for health management and healthcare, which will promote the growth of medical consumption and open up the market from the demand side.

Immunity is a very important condition when fighting against COVID-19. Through this epidemic, the public's attention to immunity has increased significantly, and the awareness of disease prevention, early medical treatment, treatment methods and drugs, disease prognosis and harm has also been deeper, and the research and development of related drugs and reagents is bound to receive more attention. This will enable the Intravenous Immunoglobulin (IVIg) industry to attract more attention, promote product innovation and development, and stimulate market vitality. It is expected that more pharmaceutical companies will strengthen the R&D and manufacturing of such drugs.

The new crown epidemic has caused the current global plasma collection stations to basically stop the plasma donation. Due to the quarantine period, the stock of plasma must be qualified again after 3 months before it can be put into plasma production. If the epidemic control in European and American countries continues to be unclear, the resumption of pulp mining will become more difficult, which will lead to insufficient supply of pulp. In such a situation where demand exceeds supply, the price of Intravenous Immunoglobulin (IVIg) products will rise rapidly in the short term.

Strength

Rising in the prevalence of immunodeficiency diseases.
Development of cost-Effective therapeutics through large-scale production.
The rapid technological progress of IVIG products.
Huge distribution channels also promote the development of the market.

Weakness

High cost of therapy.
Fierce competition.

Opportunity

Development of the health care infrastructure.
Increasing global population aging.
Developing countries in the Asia-Pacific region, such as China and India, have huge potential markets.

Threat

Stringent government regulations.
Negative effects of the economic downturn.
Tax changes that affect profits or business models.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

CSL Behring Biopharmaceuticals Ltd. is one of the major players operating in the Intravenous Immunoglobulin (IVIg) market, holding a share of 16.75% in 2020.

CSL Behring develops, manufactures, and markets protein-based therapies. The Company offers bleeding disorders, fluid replacement, hereditary angioedema, immunoglobulin, pulmonary, and wound healing plasma-derived and recombinant therapies.

Grifols develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.

Segmentation Overview:

Among different product types, IVIg Liquid segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Autoimmune Disease segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Intravenous Immunoglobulin (IVIg) market covered in Chapter 3:

ADMA Biologics, Inc.
LFB group
Baxter International Inc.
China Biologics Products, Inc.
Takeda Pharmaceuticals Hualan Biological Engineering Inc.
Grifols
CSL Behring
Octapharma
Shanghai RAAS Blood Products Co. Ltd.
Kedrion Biopharma Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Intravenous Immunoglobulin (IVIg) market from 2018 to 2029 is primarily split into:

IVIg Liquid
IVIg Powder

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Intravenous Immunoglobulin (IVIg) market from 2018 to 2029 covers:

Immunodeficiency
Autoimmune Disease
Acute Infection

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)